Please Wait.....
Report
Global Dermatological Drugs Market Report and Forecast 2024-2032
Market Report (7 days) I 2024-02-07 I 160 Pages I EMR Inc.
Global Dermatological Drugs Market Report and Forecast 2024-2032
Global Dermatological Drugs Market Outlook
The global dermatological drugs market size was valued at USD 22.59 billion in 2023, driven by increasing shift towards biologics and targeted therapies across the globe. The market size is anticipated to grow at a CAGR of 11.3% during the forecast period of 2024-2032 to achieve a value of USD 59.2 billion by 2032.
Dermatological Drugs: Introduction
Dermatological drugs are medications specifically formulated to treat skin conditions and diseases. They encompass a wide range of products, including topical creams, ointments, gels, and systemic medications like oral pills and injectables. These drugs are used to treat various conditions such as acne, dermatitis, psoriasis, skin infections, and skin cancer. The choice of medication depends on the specific condition, its severity, and the patient's overall health, aiming to relieve symptoms, improve skin appearance, and prevent complications.
Key Trends in the Global Dermatological Drugs Market
There's a significant shift towards biologics and targeted therapies, particularly for chronic conditions like psoriasis and atopic dermatitis. These treatments focus on specific pathways or cells involved in the disease process, offering more efficacy and fewer side effects compared to traditional therapies.
Personalized or precision medicine approaches are becoming more prevalent, where treatments are tailored to individual patient characteristics, genetic makeup, or specific biomarkers.
Advances in formulation technology are improving the efficacy and patient compliance of topical treatments. Innovations include better drug delivery systems that enhance penetration of active ingredients and controlled-release mechanisms.
There's a growing market for cosmetic dermatological products, driven by an increasing emphasis on appearance and anti-aging. This includes treatments for wrinkles, pigmentation disorders, and hair loss.
Telemedicine and digital health apps are gaining traction for diagnosing and managing skin conditions. These technologies offer greater accessibility to dermatological care, particularly in underserved areas or during situations like the COVID-19 pandemic.
Research in regenerative medicine and stem cells is opening up new possibilities for treating skin conditions. This includes therapies for wound healing, scar reduction, and potentially even reversing hair loss.
The global increase in skin conditions, partly due to aging populations and environmental factors, is driving demand for dermatological treatments.
Despite the growth, companies in the dermatological drug market face challenges related to regulatory hurdles, pricing pressures, and reimbursement issues, impacting market dynamics and access to new treatments.
Global Dermatological Drugs Market Segmentation
Market Breakup by Diseases
- Acne
- Dermatitis
- Psoriasis
- Skin Cancer
- Rosacea
- Alopecia
- Others
Market Breakup by Type
- Prescription-based Drugs
- Over-the-Counter Drugs
Market Breakup by Route of Administration
- Topical Administration
- Oral Administration
- Parenteral Administration
- Others
Market Breakup by End User
- Hospitals
- Homecare
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Dermatological Drugs Market Overview
In North America, the dermatological drugs market is advanced and dynamic, driven by a high focus on aesthetic appearance and quality of life. The region sees significant research and development activities, leading to the introduction of innovative treatments, including biologics for conditions like psoriasis and atopic dermatitis. Consumer awareness about skin health is high, fueling the demand for both prescription and over-the-counter skincare products. Regulatory support for rapid approval of breakthrough therapies also contributes to market dynamics.
Europe's market is characterized by stringent regulatory standards ensuring the safety and efficacy of dermatological drugs. There's a strong focus on research, with numerous initiatives aimed at understanding skin diseases at a molecular level and developing targeted treatments. Public healthcare systems in many European countries provide broad access to dermatological care, supporting market growth. The market is also influenced by a growing demand for cosmetic and anti-aging products alongside treatments for serious skin conditions.
The market in the Asia-Pacific region is rapidly expanding, driven by increasing consumer income, changing lifestyles, and a growing emphasis on personal appearance. The region has a high demand for skincare products, including those for acne, pigmentation disorders, and anti-aging. Cultural factors and climatic conditions also influence the prevalence of certain skin conditions, shaping market trends. However, the market is diverse, with variations in healthcare access and regulatory landscapes across different countries.
Global Dermatological Drugs Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
- AbbVie Inc. (Allergan PLC)
- Amgen Inc.
- Galderma
- GlaxoSmithKline Plc.
- Leo Pharma
- Johnson & Johnson
- Novartis AG
- Organon International (Merck & Co. Inc.)
- Pfizer Inc.
- Sun Pharmaceutical Industries Limited
- Sanofi
- Bausch Health Companies Inc
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- AstraZeneca
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Dermatological Drugs Market Overview
3.1 Global Dermatological Drugs Market Historical Value (2017-2023)
3.2 Global Dermatological Drugs Market Forecast Value (2024-2032)
4 Global Dermatological Drugs Market Landscape
4.1 Global Dermatological Drugs Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Dermatological Drugs Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Indication
4.2.3 Analysis by Route of Administration
5 Global Dermatological Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter's Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Dermatological Drugs Market Segmentation
6.1 Global Dermatological Drugs Market by Diseases
6.1.1 Market Overview
6.1.2 Acne
6.1.3 Dermatitis
6.1.4 Psoriasis
6.1.5 Skin Cancer
6.1.6 Rosacea
6.1.7 Alopecia
6.1.8 Others
6.2 Global Dermatological Drugs Market by Type
6.2.1 Market Overview
6.2.2 Prescription-based Drugs
6.2.3 Over-the-Counter Drugs
6.3 Global Dermatological Drugs Market by Route of Administration
6.3.1 Market Overview
6.3.2 Topical Administration
6.3.3 Oral Administration
6.3.4 Parenteral Administration
6.3.5 Others
6.4 Global Dermatological Drugs Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Homecare
6.5 Global Dermatological Drugs Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Dermatological Drugs Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Dermatological Drugs Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Dermatological Drugs Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Dermatological Drugs Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Dermatological Drugs Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 AbbVie Inc. (Allergan PLC).
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.1.5 Certifications
17.2 Amgen Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.2.5 Certifications
17.3 Galderma
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.3.5 Certifications
17.4 GlaxoSmithKline Plc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.4.5 Certifications
17.5 Leo Pharma
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.5.5 Certifications
17.6 Johnson & Johnson
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.6.5 Certifications
17.7 Novartis AG
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.7.5 Certifications
17.8 Organon International (Merck & Co. Inc.)
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.8.5 Certifications
17.9 Pfizer Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.9.5 Certifications
17.10 Sun Pharmaceutical Industries Limited
17.10.1 Financial Analysis
17.10.1 Product Portfolio
17.10.2 Demographic Reach and Achievements
17.10.3 Mergers and Acquisition
17.10.4 Certifications
17.11 Sanofi
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisition
17.11.5 Certifications
17.12 Bausch Health Companies Inc
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisition
17.12.5 Certifications
17.13 Bristol-Myers Squibb Company
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisition
17.13.5 Certifications
17.14 F. Hoffmann-La Roche Ltd
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisition
17.14.5 Certifications
17.15 AstraZeneca
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisition
17.15.5 Certifications
18 Global Dermatological Drugs Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security